NCT03078036 International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study Status COMPLETED Phase N/A
NCT03075527 A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma Status TERMINATED Phase PHASE2
NCT03073447 WAMIF : Young Women Presenting Acute Myocardial Infarction in France Status COMPLETED Phase NA
NCT03071016 Usage of Dapagliflozin in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients Status COMPLETED Phase N/A
NCT03063710 Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan Status NO_LONGER_AVAILABLE Phase N/A
NCT03060512 To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation Status COMPLETED Phase PHASE4
NCT03057145 Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT03057106 Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03053297 Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer) Status TERMINATED Phase N/A
NCT03047135 Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03043872 Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT03038477 A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection Status WITHDRAWN Phase PHASE2
NCT03036150 A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease Status COMPLETED Phase PHASE3
NCT03036124 Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure Status COMPLETED Phase PHASE3